MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list
Author(s): ,
James Trotter
Affiliations:
Baylor Scott & White Liver Consultants of Texas – Dallas, Liver Health – Austin, USA
,
Patrick S. Kamath
Affiliations:
Mayo Clinic College of Medicine, Rochester, MN, USA
Alastair O'Brien
Affiliations:
Institute of Liver and Digestive Health, University College London, UK
Corresponding author. Address: Institute of Liver and Digestive Health, University College London, UK; Tel.: +442076796851.
EASL LiverTree™. O'Brien A. Dec 1, 2018; 256730
Alastair O'Brien
Alastair O'Brien

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
References
Discussion Forum (0)
Rate & Comment (0)
This article does not have an abstract to display.
[1]. C. Valerio - Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion
[2]. L. Turco - Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis
[3]. P. Angeli - Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
[4]. B.A. Runyon - Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012
[5]. R. Garcia-Martinez - Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications
[6]. P. Angeli - Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites
[7]. T.T. Guo - Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis
[8]. K. Bari - The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis
[9]. E. Solà - Midodrine and albumin for preventing complications in patients with cirrhosis awaiting liver transplantation
[10]. P. Caraceni - ANSWER Study Investigators Long-term albumin administration in decompensated cirrhosis: an open-label randomised trial
[11]. M. Domenicali - Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis
[12]. ClinicalTrials.gov Identifier: NCT03451292.
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies